Gelesis logo

Gelesis(OTC) GLSHQ

Market Cap$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Gelesis last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-21
Gelesis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-09
1 month+0%USD 0.002026-07-22
3 month+0%USD 0.002026-06-22
Year to date-99%USD 0.002025-12-31
1 year+0%USD 0.002025-07-30
3 year-100%USD 0.052023-09-22
5 year-100%USD 9.962021-09-22
Since inception-100%USD 9.852020-08-24

Gelesis Financials at a Glance

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.14M

Net Income (TTM)

-$51.67M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-302.61 (Low)

Price

$0.00

Volume

125

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 16, 2026

GLSHQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Gelesis

Gelesis Holdings, Inc. is a commercial-stage biotherapeutics company focused on developing biomimetic solutions to address obesity and chronic gastrointestinal conditions. The company is known for its innovative product PLENITY, which aids in weight management, and has a promising pipeline of additional therapies.

Products and Services
  • PLENITY: An oral, non-stimulant product for weight management
  • GS200: Targets weight reduction for prediabetes and type 2 diabetes
  • GS500: Aims to treat functional constipation
Growth Outlook
  • Recent product launches have increased market visibility and consumer interest
  • Pipeline includes multiple promising therapies addressing significant health issues
  • Strategic partnerships may enhance research and development capabilities
Financial Highlights
  • Q2 2023 revenue of $1.1 million, a decrease from $1.75 million in Q1 2023
  • Net income for Q2 2023 was -$7.68 million, reflecting ongoing operational challenges
  • Total assets of $95.88 million, indicating substantial investment in R&D and infrastructure
Gelesis Holdings, Inc. operates in the biotechnology sector, focusing on innovative solutions for obesity and gastrointestinal disorders. The flagship product, PLENITY, is designed to assist individuals in managing their weight effectively. The company also has several products in its pipeline, including GS200 and GS500, which target weight reduction and functional constipation, respectively. Despite facing financial challenges, including a net income loss of $7.68 million in the most recent quarter, Gelesis continues to invest in research and development. The total assets of approximately $95.88 million reflect a commitment to advancing its product offerings. The company’s growth outlook remains positive, driven by recent product launches and potential strategic partnerships that could enhance its market position. Investors may find Gelesis Holdings, Inc. an intriguing opportunity within the biotechnology space, particularly given its focus on addressing critical health issues through innovative therapies.
AI Generated • Oct 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

100

CEO

Yishai Zohar

Website

www.gelesis.com

Headquarters

Boston, MA 02116, US

GLSHQ Financials

Key Financial Metrics (TTM)

Gross Margin

-6.95%

Operating Margin

-472.72%

Net Income Margin

-221.71%

Return on Equity

32.19%

Return on Capital

-327.37%

Return on Assets

-55.29%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

73.34M

Volume

125

Avg. Volume

3.6

Financials (TTM)

Gross Profit

-$7.45M

Operating Income

-$66.34M

EBITDA

-$40.21M

Operating Cash Flow

-$46.04M

Capital Expenditure

-$4.30M

Free Cash Flow

-$50.33M

Cash & ST Invst.

$7.91M

Total Debt

$61.88M

Gelesis Performance Analysis

Gelesis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 11,185,000N/A
20222022-12-31USD 25,767,000130.4%
Gelesis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30-25.9%
Q42022-12-31-60.5%
Q12023-03-31-33.3%
Q22023-06-30-36.9%
Gelesis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -32.89N/A
20222022-12-31USD -1.35-95.9%
Gelesis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32022-09-30-17.6%
Q42022-12-31-65.0%
Q12023-03-3178.3%
Q22023-06-30-39.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2023YOY CHG

Revenue

$1.11M

-87.7%

Gross Profit

$609.00K

-85.5%

Gross Margin

55.01%

N/A

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.08

N/A

Employees

93

N/A

Net Income

-$7.68M

+39.0%

EBITDA

-$5.05M

+55.5%

Quarterly Fundamentals

Name
Q2 2023YOY CHG

Total Cash

$7.91M

-68.8%

Total Debt

$61.88M

+77.0%

Accounts Receivable

$9.56M

-32.2%

Inventory

$5.69M

-69.8%

Long Term Debt

$27.96M

-10.5%

Short Term Debt

$33.91M

+809.9%

Return on Assets

-55.29%

N/A

Return on Invested Capital

-4.88%

N/A

Free Cash Flow

$599.00K

+107.8%

Operating Cash Flow

$617.00K

+113.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNBTGenerex Biotechnology Corporation
$0.00+0.00%
GTHRGeneThera, Inc.
$0.00+0.00%
CRYOAmerican CryoStem Corporation
$0.00-99.75%
CRXMGene Biotherapeutics, Inc.
$0.00+9900.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About GLSHQ

What is the current price of Gelesis?

Gelesis is trading at $0.00 per share.

What is the 52-week range for Gelesis?

Over the past 52 weeks, Gelesis has traded between $0.00 and $0.00.

How much debt does Gelesis have?

As of the most recent reporting period, Gelesis reported total debt of $62.26M.

How much cash does Gelesis have on hand?

Gelesis reported $7.41M in cash and cash equivalents in its most recent financial results.

What is Gelesis’s dividend yield?

Gelesis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services